About veriNOS pharmaceuticals
veriNOS pharmaceuticals is a Healthcare company based in Wurzburg (Germany) founded in 1998. veriNOS pharmaceuticals has raised $62.7 million across 8 funding rounds from investors including 3i Group, KfW and The Hanseatic Group. Its chief executive, as recorded, is Christian Wandersee. Its focus areas include Life Sciences, Neurology, Drugs and Neural Injury. Its legal entity is veriNOS pharmaceuticals GmbH.
Company details
Developer of therapeutics for retina and brain diseases. It offers a lead product Ronopterin which is a selective iNOS inhibitor which reduces inflammatory response and edema formation for the treatment of traumatic brain injury and diabetic retinopathy.
- Headquarters Wurzburg, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website verinos-pharma.com
- Social LinkedIn
- Legal Name Verinos Pharmaceuticals Gmbh
- Total Equity Funding$62.7M (USD)
in 8 rounds
- Latest Funding Round$10.67M (USD), Series G
Jul 2019
- Investors3i Group
& 11 more
Funding Insights of veriNOS pharmaceuticals
veriNOS pharmaceuticals has successfully raised a total of $62.7M across 8 strategic funding rounds. The most recent funding activity was a Series G round of $10.67 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.7M
- Total Rounds 8
- Last Round Series G — $10.67M
- First Round $6M
(Aug 2001)
- Investors Count 12
All 8 funding rounds of veriNOS pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $10.67M | Series G | – | HeidelbergCapital | |
| Jan 2016 | $21.84M | Series G | – | Entrepreneurs Fund, HeidelbergCapital | |
| Jun 2013 | $6.5M | Series F | – | Entrepreneurs Fund, HeidelbergCapital | |
| May 2009 | $5.96M | Series D | – | EMBL Ventures, HeidelbergCapital | |
| Jan 2006 | $11.73M | Series B | – | Bayern Kapital, KfW | |
| Dec 2004 | Series B | – | Entrepreneurs Fund, 3i Group | – | |
| Feb 2004 | Grant | – | – | ||
| Aug 2001 | $6M | Series A | – | 3i Group | – |
12 investors in total: 12 institutional.
Investors in veriNOS pharmaceuticals
veriNOS pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include 3i Group, KfW and The Hanseatic Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
High-tech industries are targeted for investments by Bayern Kapital. | bayernkapital.de | Landshut, Germany | ||
Financial services, investment management, and capital allocation in various sectors. | future-capital.com | |||
| creathor.com | ||||
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe | entrepreneursfund.com | London, United Kingdom | ||
| fortrockcapital.com | ||||
Private equity funds are managed for asset returns. | 2004 | hansagrp.com | St. Peter Port, United Kingdom | |
Life science companies are supported through strategic investments. | embl-ventures.com | Heidelberg, Germany | ||
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Operates as a firm specializing in direct secondary market investments. | 2007 | heidelbergcapital.de | Heidelberg, Germany | |
Serves as a brand specializing in coffee and teas. | 1907 | ringtons.co.uk | Newcastle Upon Tyne, United Kingdom |
Investor details for veriNOS pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of veriNOS pharmaceuticals
1 people are tracked at veriNOS pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christian Wandersee | CEO | Leadership |
Complete people profiles for veriNOS pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of veriNOS pharmaceuticals
3 dated milestones of veriNOS pharmaceuticals across 21 years, from founding to its latest funding, stage changes and deals.
- Founded veriNOS pharmaceuticals is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series G, of $10.7M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verinos Pharmaceuticals
Complete news archive for veriNOS pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about veriNOS pharmaceuticals
veriNOS pharmaceuticals was founded in 1998 and raised its 1st funding round 3 years after it was founded.
veriNOS pharmaceuticals is headquartered in Wurzburg, Germany. It is registered at Wurzburg, Bavaria, Germany.
Christian Wandersee is the CEO of veriNOS pharmaceuticals, as recorded in our data.
veriNOS pharmaceuticals is a funded company, having raised a total of $62.7M across 8 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Aug 2001.
Developer of therapeutics for retina and brain diseases. It offers a lead product Ronopterin which is a selective iNOS inhibitor which reduces inflammatory response and edema formation for the treatment of traumatic brain injury and diabetic retinopathy.
veriNOS pharmaceuticals has 12 investors. Key investors include 3i Group, KfW, The Hanseatic Group, HeidelbergCapital, and Bayern Kapital.
veriNOS pharmaceuticals operates through Verinos Pharmaceuticals Gmbh.